Results 161 to 170 of about 6,464 (211)
Anidulafungin, a New Echinocandin [PDF]
Drugs, 2009 Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease.
G. Morace +3 more
core +9 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Anidulafungin: an echinocandin antifungal
Expert Opinion on Investigational Drugs, 2004Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
exaly +3 more sources
Drugs, 2004
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David, Murdoch, Greg L, Plosker
+5 more sources
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David, Murdoch, Greg L, Plosker
+5 more sources
Infectious Diseases in Clinical Practice, 2005
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found
Mahmoud Ghannoum, Maurissa D'Angelo
openaire +1 more source
Anidulafungin (LY-303366, VER002) is a semisynthetic derivative of echinocandin B and a potent antifungal agent active against a wide spectrum of fungal pathogens. We reviewed published papers, abstracts, and data to provide an overview focusing on the microbiology of anidulafungin and its promise for treating fungal infections. Anidulafungin was found
Mahmoud Ghannoum, Maurissa D'Angelo
openaire +1 more source
Expert Opinion on Drug Safety, 2006
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +2 more sources
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi.
openaire +2 more sources
Hospital Pharmacy, 2006
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Anidulafungin-Induced Alopecia
Annals of Pharmacotherapy, 2014Objetive: To report a case of a woman in whom alopecia appeared after several months of treatment with anidulafungin. Case Summary: A 34-year-old woman with chronic femoral osteomyelitis with the presence of persistent suppuration, developed a Candida albicans infection, isolated in the fistula exudate cultures. After initial failures of single therapy
Ruiz-Ramos J +5 more
openaire +3 more sources
IDrugs : the investigational drugs journal, 2004
Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection.
openaire +2 more sources
Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection.
openaire +2 more sources